Millennium/Takeda's Phase III IBD Drug Promises Improved Safety
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Millennium Pharmaceuticals has launched Phase III trials of its anti-inflammatory biologic MLN0002 in two kinds of inflammatory bowel disease, the Takeda subsidiary announced Jan. 2
You may also be interested in...
Millennium Initiates New Clinical Program For Ulcerative Colitis Candidate
Program includes Phase II dose-ranging study and Phase I study in healthy volunteers.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.